Portal de Periódicos da CAPES

P399 Cost-effectiveness of utilising proactive Infliximab therapeutic drug monitoring for inflammatory bowel disease in routine clinical practice

2019; Oxford University Press; Volume: 13; Issue: Supplement_1 Linguagem: Inglês

10.1093/ecco-jcc/jjy222.523

1876-4479

Jenny T. van der Steen, Mary McCormack, C McShane, Martin Healy, Vivion Crowley, Úna Kennedy, O.A. Hayes, Cara Dunne, Karen Hartery, Susan McKiernan, F MacCarthy, David Kevans,

Chronic Lymphocytic Leukemia Research

Therapeutic drug monitoring(TDM) is increasingly utilised in IBD practice to guide dosing of anti-TNFs. Proactive TDM assessment has not, however, been clearly shown to improve clinical outcomes compared with empiric dose optimisation. The aim of our study was to assess whether a proactive-TDM strategy, with the aim of dosing patients to an IFX-level in the therapeutic range, is a cost-effective strategy in routine practice. IFX TDM has been available at SJH for a 1-year period. On a pilot basis, IBD patients receiving IFX had a single trough sample collected. IFX-levels and antibody-to-IFX concentrations (ADA) were determined. IFX levels from 3 to 7 µg/l were considered therapeutic. ADA of 50 AU/ml and above were considered significant . IFX treatment decisions based on TDM were documented. Costs/savings related to TDM use were estimated by documenting alterations to IFX regimens prompted by TDM and extrapolating annualised total dose increases / reductions. A total of 64 IBD patients were included, 51% male, 63% Crohn's disease. Twenty-seven per cent, 43% and 30% of patients had a therapeutic, subtherapeutic and supratherapeutic IFX-level. n = 21 (33%) had significant ADA present. n = 35 patients (55%) patients had alterations to IFX dosing based on TDM: 23% had IFX dosing interval increased, 20% had IFX dosing interval decreased and 11% discontinued IFX therapy. The use of proactive-TDM was found to be cost-effective with annual savings of €70,083.34. While Anti-TNF TDM has certainly been shown to be of value in the setting of loss of response to treatment, it remains unclear whether a proactive-TDM improves clinical outcomes. Our study suggests proactive TDM may at least be a cost-effective strategy.